Metastatic breast cancer affects people in many ways. The symptoms experienced by each person will vary based on the parts of ...

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

Several studies show that isolation is very common among those diagnosed with metastatic breast cancer. However, there are ...

BriaCell Therapeutics (TSX:BCT) is reporting that the first metastatic breast cancer patient treated with its Bria-OTS ...

The FDA has approved an expanded label for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, which ...

Lung metastasis (from metastatic breast cancer) resolved - after only 2 months (4 doses) of treatment with Bria-OTS™ ...

DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and ...

The author reflects on living with HER2-positive metastatic breast cancer for over a decade, highlighting significant milestones and challenges. The eleventh year is viewed as a new beginning, ...

The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, ...

Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...

BriaCell Therapeutics Corp. (BCTX, BCTXW) is down by 4.71 percent during Monday morning trading, following the announcement of a ...